Stay updated on Durvalumab in Resectable Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.

Latest updates to the Durvalumab in Resectable Lung Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page footer now displays Revision: v3.3.2, replacing the previous v3.3.1.SummaryDifference0.1%

- Check13 days agoChange DetectedRevision: v3.3.1 was released. The record now includes new sections such as Outcome Measures, Adverse Events, Baseline Characteristics, and Participant Flow, and notes that Quality Control review has not concluded as of 2025-11-17.SummaryDifference0.9%

- Check20 days agoChange DetectedAdded a 'Results Submitted' status to the study record and removed the 'No Results Posted' notice as well as the government funding lapse notice.SummaryDifference0.4%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe Record History for NCT03800134 shows many version updates, with recurring changes to Study Status, Contacts/Locations, and IPDSharing, reflecting ongoing adjustments to trial status and participating sites. These updates affect current participation information and how to contact researchers.SummaryDifference0.1%

- Check63 days agoChange Detected- Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.SummaryDifference9%

- Check70 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.2%

Stay in the know with updates to Durvalumab in Resectable Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab in Resectable Lung Cancer Clinical Trial page.